FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

Paramagnetic rim lesions may help assess MS risk in people with radiologically isolated syndrome before symptoms appear.

BALTIMORE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Early ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

A supplement made from broccoli, green tea, and turmeric has slowed the rise of a prostate cancer blood marker in men monitored for early disease. That slowdown reframes how long some patients may ...

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...

Francis Medical recently won FDA 510(k) clearance for its Vanquish Water Vapor Ablation System, a new device for minimally invasive prostate ablation. The Vanquish system uses water vapor for focal ...